NT5DC2 and pancreatic adenocarcinoma: The findings suggest that NT5C2 and NT5DC2 may be targets and valuable biomarkers to establish personalized treatments for patients with PAAD, which may help with the development of improved diagnostic and therapeutic modalities to improve patient prognoses.